Login
$RVMD
$166.04 -$0.83 (0.5%) After hours

$RVMD SEC Filings

Filed On Filing
16 Nov 2026 144
13 Nov 2026 Form 4: Anders Jack, Chief Financial Officer

Received 35,750 shares by exercise or conversion ($1.04M) · Sold 35,750 shares ($6.72M)

13 Nov 2026 Form 4: Borisy Alexis, Director

Gave 10,625 shares as a gift

12 Nov 2026 Form 4: Mancini Anthony, See Remarks

Received 811 shares by exercise or conversion ($27.3K) · Sold 811 shares ($162K)

12 Nov 2026 144
05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy

30 Oct 2026 SCHEDULE 13G
28 Oct 2026 Form 4: Mancini Anthony, See Remarks

Received 2,310 shares by exercise or conversion ($77.7K) · Sold 2,310 shares ($432K)

13 Oct 2026 8-K: Creation of a Direct Financial Obligation; Other Events

The information set forth under Item 8.01 below under the heading “Royalty Pharma Tranche A Loan” is incorporated by reference into this Item 2.03.

01 Oct 2026 Form 4: Sandler Alan B., Chief Development Officer

Received 6,000 shares by exercise or conversion ($353K) · Sold 6,309 shares ($1.28M)

29 Sep 2026 Form 4: Cislini Jeff, SVP & General Counsel

Sold 765 shares ($159K)

29 Sep 2026 144
28 Sep 2026 Form 4: Mancini Anthony, See Remarks

Sold 587 shares ($117K) · Received 3,121 shares by exercise or conversion ($105K) · Sold 3,121 shares ($626K)

25 Sep 2026 144
24 Sep 2026 Form 4: Anderson Elizabeth M, Director

Received 5,070 shares by exercise or conversion ($5.68K) · Sold 10,143 shares ($1.96M)

24 Sep 2026 144
22 Sep 2026 Form 4: Mancini Anthony, See Remarks

Sold 1,764 shares ($347K)

22 Sep 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support